Temporal glomerular gene expression dynamics during disease progression in a mouse model of hypertension-accelerated diabetic kidney disease

Abstract

Background: The current understanding of diabetic kidney disease (DKD) has significant gaps regarding the underlying pathogenesis. In this study, we aimed to characterize the temporal progression of DKD using a state-of-the-art mouse model of hypertension-accelerated disease, integrating kidney biomarker analysis, histopathology, and glomerular transcriptomic profiling.

Methods: Female diabetic db/db mice received a single intravenous dose of adeno-associated virus-mediated renin overexpression (ReninAAV, week 5) and underwent uninephrectomy (UNx, week 4). db/db UNx-ReninAAV mice were terminated at weeks 1, 4, 8, and 12 (n = 7–8 per group). Female db/m mice were used as healthy controls. Study endpoints included plasma and urine biochemistry, glomerulosclerosis scoring, quantitative kidney histology, and RNA sequencing of glomeruli isolated using laser-capture microdissection.

Results: db/db UNx-ReninAAV mice developed progressive albuminuria (from week 4) and glomerulosclerosis (from week 8). A pathway analysis of clustered gene regulations revealed broad glomerular transcriptome perturbations with signatures of increased extracellular matrix (ECM) turnover from week 8 and early onset of metabolic dysfunction. Markers of glomerular cell types and injury exhibited temporal regulation over the course of DKD, with early and sustained downregulation of endothelial markers, heterogeneous regulation of podocyte markers, and significant mesangial and parietal epithelial aberrations. Furthermore, the upregulation of cell injury markers confirmed progressive glomerular injury in the model.

Conclusion: The db/db UNx-ReninAAV mouse model exhibits distinct temporal dynamics in glomerular cell markers, metabolic dysregulation, ECM remodeling, and injury. Together, these results highlight the utility of the db/db UNx-ReninAAV model as a relevant preclinical platform for studying progressive DKD.

Keywords

db/db UNx-ReninAAV mouse / diabetic kidney disease / glomerular transcriptomics / glomerulosclerosis / laser-capture microdissection

References

[1] Ferrari AJ, Santomauro DF, Aali A, et al. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403(10440): 2133-2161.

[2] Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR. Targeting the progression of chronic kidney disease. Nat Rev Nephrol. 2020; 16(5): 269-288.

[3] Yu SMW, Bonventre JV. Acute kidney injury and progression of diabetic kidney disease. Adv Chronic Kidney Dis. 2018; 25(2): 166-180.

[4] Chen Y, Lee K, Ni Z, He JC. Diabetic kidney disease: challenges, advances, and opportunities. Kidney Dis. 2020; 6(4): 215-225.

[5] Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015; 1(1): 15018.

[6] Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: A Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016; 67(5): 728-741.

[7] Stevens PE. Evaluation and Management of Chronic Kidney Disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013; 158(11): 825.

[8] Harjutsalo V, Groop PH. Epidemiology and risk factors for diabetic kidney disease. Adv Chronic Kidney Dis. 2014; 21(3): 260-266.

[9] Kelly JT, Su G, Zhang L, et al. Modifiable lifestyle factors for primary prevention of CKD: A systematic review and meta-analysis. J Am Soc Nephrol. 2021; 32(1): 239-253.

[10] Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020; 383(23): 2219-2229.

[11] Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024; 391(2): 109-121.

[12] Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020; 383(15): 1425-1435.

[13] Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375(4): 323-334.

[14] Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380(24): 2295-2306.

[15] McCullough KP, Morgenstern H, Saran R, Herman WH, Robinson BM. Projecting ESRD incidence and prevalence in the United States through 2030. J Am Soc Nephrol. 2019; 30(1): 127-135.

[16] Gil CL, Hooker E, Larrivée B. Diabetic kidney disease, endothelial damage, and podocyte-endothelial crosstalk. Kidney Med. 2021; 3(1): 105-115.

[17] Lin JS, Susztak K. Podocytes: the weakest link in diabetic kidney disease? Curr Diab Rep. 2016; 16(5): 45.

[18] Qi H, Casalena G, Shi S, et al. Glomerular endothelial mitochondrial dysfunction is essential and characteristic of diabetic kidney disease susceptibility. Diabetes. 2017; 66(3): 763-778.

[19] Nagasu H, Satoh M, Kiyokage E, et al. Activation of endothelial NAD(P)H oxidase accelerates early glomerular injury in diabetic mice. Lab Investig. 2016; 96(1): 25-36.

[20] Ebefors K, Bergwall L, Nyström J. The glomerulus according to the mesangium. Front Med (Lausanne). 2022; 8: 8.

[21] Thomas HY, Ford Versypt AN. Pathophysiology of mesangial expansion in diabetic nephropathy: mesangial structure, glomerular biomechanics, and biochemical signaling and regulation. J Biol Eng. 2022; 16(1): 19.

[22] Kawaguchi T, Hasegawa K, Yasuda I, et al. Diabetic condition induces hypertrophy and vacuolization in glomerular parietal epithelial cells. Sci Rep. 2021; 11(1): 1515.

[23] Liu W b, Huang G r, Liu B l, et al. Single cell landscape of parietal epithelial cells in healthy and diseased states. Kidney Int. 2023; 104(1): 108-123.

[24] Østergaard MV, Secher T, Christensen M, et al. Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease. Am J Physiol Renal Physiol. 2021; 321(2): F149-F161.

[25] Harlan SM, Heinz-Taheny KM, Sullivan JM, et al. Progressive renal disease established by renin-coding adeno-associated virus–driven hypertension in diverse diabetic models. J Am Soc Nephrol. 2018; 29(2): 477-491.

[26] Dalbøge LS, Christensen M, Madsen MR, et al. Nephroprotective effects of Semaglutide as mono- and combination treatment with lisinopril in a mouse model of hypertension-accelerated diabetic kidney disease. Biomedicine. 2022; 10(7): 1661.

[27] Sembach FE, Ægidius HM, Fink LN, et al. Integrative transcriptomic profiling of a mouse model of hypertension-accelerated diabetic kidney disease. Dis Model Mech. 2021; 14(10):dmm049086.

[28] Woroniecka KI, Park ASD, Mohtat D, Thomas DB, Pullman JM, Susztak K. Transcriptome analysis of human diabetic kidney disease. Diabetes. 2011; 60(9): 2354-2369.

[29] Ju W, Greene CS, Eichinger F, et al. Defining cell-type specificity at the transcriptional level in human disease. Genome Res. 2013; 23(11): 1862-1873.

[30] Wu H, Gonzalez Villalobos R, Yao X, et al. Mapping the single-cell transcriptomic response of murine diabetic kidney disease to therapies. Cell Metab. 2022; 34(7): 1064-1078.e6.

[31] Lake BB, Menon R, Winfree S, et al. An atlas of healthy and injured cell states and niches in the human kidney. Nature. 2023; 619(7970): 585-594.

[32] Sembach FE, Fink LN, Johansen T, et al. Impact of sex on diabetic nephropathy and the renal transcriptome in UNx db/db C57BLKS mice. Physiol Rep. 2019; 7(24): 1-9.

[33] Østergaard MV, Sembach FE, Skytte JL, et al. Automated image analyses of glomerular hypertrophy in a mouse model of diabetic nephropathy. Kidney360. 2020; 1(6): 469-479.

[34] Marstrand-Jørgensen AB, Sembach FE, Bak ST, et al. Shared and distinct renal transcriptome signatures in 3 standard mouse models of chronic kidney disease. Nephron. 2024; 148(7): 487-502.

[35] Soendergaard C, Nielsen OH, Skak K, Røpke MA, Seidelin JB, Kvist PH. Objective quantification of immune cell infiltrates and epidermal proliferation in psoriatic skin: A comparison of digital image analysis and manual counting. Appl Immunohistochem Mol Morphol. 2016; 24(6): 453-458.

[36] Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12): 1-21.

[37] Dobin A, Davis CA, Schlesinger F, et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics. 2013; 29(1): 15-21.

[38] Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995; 57(1): 289-300.

[39] Murtagh F, Legendre P. Ward's hierarchical agglomerative clustering method: which algorithms implement Ward's criterion? J Classif. 2014; 31(3): 274-295.

[40] Federico A, Monti S. hypeR: an R package for geneset enrichment workflows. Bioinformatics. 2020; 36(4): 1307-1308.

[41] Castanza AS, Recla JM, Eby D, Thorvaldsdóttir H, Bult CJ, Mesirov JP. Extending support for mouse data in the molecular signatures database (MSigDB). Nat Methods. 2023; 20(11): 1619-1620.

[42] Milacic M, Beavers D, Conley P, et al. The Reactome pathway knowledgebase 2024. Nucleic Acids Res. 2024; 52(D1): D672-D678.

[43] Yang J, Liu Z. Mechanistic pathogenesis of endothelial dysfunction in diabetic nephropathy and retinopathy. Front Endocrinol (Lausanne). 2022; 13: 13.

[44] Mahtal N, Lenoir O, Tharaux PL. Glomerular endothelial cell crosstalk with podocytes in diabetic kidney disease. Front Med (Lausanne). 2021; 8:659013.

[45] Kravets I, Mallipattu SK. The role of podocytes and podocyte-associated biomarkers in diagnosis and treatment of diabetic kidney disease. J Endocr Soc. 2020; 4(4): 1-11.

[46] Li ZH, Guo XY, Quan XY, et al. The role of parietal epithelial cells in the pathogenesis of podocytopathy. Front Physiol. 2022; 13:832772.

[47] Harlan SM, Heinz-Taheny KM, Overstreet JM, Breyer MD, Harris RC, Heuer JG. Pathological and transcriptome changes in the ReninAAV db/db uNx model of advanced diabetic kidney disease exhibit features of human disease. Toxicol Pathol. 2018; 46(8): 991-998.

[48] Wang Y, Jin M, Cheng CK, Li Q. Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives. Front Endocrinol (Lausanne). 2023; 14: 14.

[49] Kriz W. The inability of podocytes to proliferate: cause, consequences, and origin. Anat Rec. 2020; 303(10): 2588-2596.

[50] Shankland SJ, Wang Y, Shaw AS, Vaughan JC, Pippin JW, Wessely O. Podocyte aging: why and how getting old matters. J Am Soc Nephrol. 2021; 32(11): 2697-2713.

[51] Deng B, Song A, Zhang C. Cell-cycle dysregulation in the pathogenesis of diabetic kidney disease: an update. Int J Mol Sci. 2023; 24(3): 2133.

[52] Mitrofanova A, Merscher S, Fornoni A. Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease. Nat Rev Nephrol. 2023; 19(10): 629-645.

[53] Ren L, Cui H, Wang Y, et al. The role of lipotoxicity in kidney disease: from molecular mechanisms to therapeutic prospects. Biomed Pharmacother. 2023; 161:114465.

[54] Rinschen MM, Palygin O, Guijas C, et al. Metabolic rewiring of the hypertensive kidney. Sci Signal. 2019; 12(611):eaax9760.

[55] Fan X, Yang M, Lang Y, et al. Mitochondrial metabolic reprogramming in diabetic kidney disease. Cell Death Dis. 2024; 15(6): 442.

[56] Garcia-Fernandez N, Jacobs-Cachá C, Mora-Gutiérrez JM, Vergara A, Orbe J, Soler MJ. Matrix metalloproteinases in diabetic kidney disease. J Clin Med. 2020; 9(2): 472.

[57] Qian Y, Feldman E, Pennathur S, Kretzler M, Brosius FC. From fibrosis to sclerosis. Diabetes. 2008; 57(6): 1439-1445.

[58] Cai G, Zhang X, Hong Q, et al. Tissue inhibitor of metalloproteinase-1 exacerbated renal interstitial fibrosis through enhancing inflammation. Nephrol Dial Transplant. 2008; 23(6): 1861-1875.

[59] Xu X, Jackson PL, Tanner S, et al. A Self-Propagating Matrix Metalloprotease-9 (MMP-9) Dependent Cycle of Chronic Neutrophilic Inflammation. PLoS One. 2011; 6(1):e15781.

[60] Hu Z, Cano I, Lei F, et al. Loss of the endothelial glycocalyx component EMCN leads to glomerular impairment. Circ Res. 2024; 136(1): 59-74.

[61] Daehn IS, Duffield JS. The glomerular filtration barrier: a structural target for novel kidney therapies. Nat Rev Drug Discov. 2021; 20(10): 770-788.

[62] Li X, Zhang Y, Xing X, et al. Podocyte injury of diabetic nephropathy: novel mechanism discovery and therapeutic prospects. Biomed Pharmacother. 2023; 168:115670.

[63] Zivotic M, Dundjerovic D, Naumovic R, et al. Clinicopathological relevance of PAX8 expression patterns in acute kidney injury and chronic kidney diseases. Diagnostics. 2022; 12(9): 2036.

[64] Zhang D, Gu T, Forsberg E, Efendic S, Brismar K, Gu HF. Genetic and functional effects of membrane Metalloendopeptidase on diabetic nephropathy development. Am J Nephrol. 2011; 34(5): 483-490.

[65] Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol. 2008; 294(4): F697-F701.

[66] Limonte CP, Valo E, Drel V, et al. Urinary proteomics identifies cathepsin D as a biomarker of rapid eGFR decline in type 1 diabetes. Diabetes Care. 2022; 45(6): 1416-1427.

[67] Zhao L, Zou Y, Liu F. Transforming growth factor-Beta1 in diabetic kidney disease. Front Cell Dev Biol. 2020; 8:187.

[68] Meng XM, Tang PMK, Li J, Lan HY. TGF-ß/Smad signaling in renal fibrosis. Front Physiol. 2015; 6:82.

[69] Zhang Z, Schaefer C, Jiang W, et al. A panoramic view of cell population dynamics in mammalian aging. Science. 2025; 387(6731):eadn3949.

[70] Yang S, Liu P, Zhang Y, et al. Single-cell transcriptome atlas in C57BL/6 mice encodes morphological phenotypes in the aging kidneys. BMC Nephrol. 2024; 25(1): 137.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.